Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;36(7):1516.
doi: 10.1038/s41433-021-01782-w. Epub 2021 Sep 30.

Response to: 'Comment on: 'Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae''

Magdalena Popiela  1   2 , Michael Ardern-Jones  3 , Parwez Hossain  4   5
Affiliations
Comment

Response to: 'Comment on: 'Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae''

Magdalena Popiela et al. Eye (Lond). 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Comment on

References

    1. Popiela MZ, Barbara R, Turnbull AMJ, Corden E, Martinez-Falero BS, O’Driscoll D, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye (Lond). 2021. 10.1038/s41433-020-01379-9. Epub ahead of print. - PMC - PubMed
    1. Touhouche AT, Cassagne M, Bérard E, Giordano-Labadie F, Didier A, Fournié P, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol. 2021;35:172–9. doi: 10.1111/jdv.16724. - DOI - PubMed
    1. Utine CA, Li G, Asbell P, Pflugfelder S, Akpek E. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf. 2021;19:151–6. doi: 10.1016/j.jtos.2020.05.008. - DOI - PubMed
    1. Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran THC. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8:485–90. doi: 10.1007/s40123-019-0191-9. - DOI - PMC - PubMed
    1. Treister AD, Kraff-Cooper C, Lio PA. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatol. 2018;154:1208–11. doi: 10.1001/jamadermatol.2018.2690. - DOI - PMC - PubMed

Substances